Impact of vericiguat on heart failure with reduced ejection fraction:a review
作者机构：Department of Pharmacy PracticeISF College of PharmacyMogaPunjab 142001India
出 版 物：《Global Health Journal》 (全球健康杂志（英文）)
年 卷 期：2023年第7卷第3期
页 面：123-129页
学科分类：1002[医学-临床医学] 100201[医学-内科学(含：心血管病、血液病、呼吸系病、消化系病、内分泌与代谢病、肾病、风湿病、传染病)] 10[医学]
基 金：Indo Soviet Friendship College of Pharmacy ISFCP
主 题：Vericiguat Heart failure with reduced ejection fraction Soluble guanylate cyclase stimulator Nitric oxide Cyclicguanosinemonophosphate
摘 要：Introduction:Heart failure is a major public health issue with a prevalence of about 26 million people *** nitric oxide availability,lower soluble guanylate cyclase(sGC)activity,and decreased cyclic guanosine monophosphate(cGMP)production are the causes of HF s *** prescribed under the brand name Verquvo was approved by *** and Drug Administration(FDA)in January *** is a novel agent and the first sGC stimulator which helps to treat patients suffering from heart failure with reduced ejection fraction(HFrEF).Objective:The mechanism of action(cGMP pathway)of vericiguat,its clinical trials,its use in the treatment of heart failure,and its possible future aspects in therapeutic recommendations are all covered in this *** will also raise awareness amongst healthcare professionals about the pharmacokinetic and pharmacodynamic parameters,dosing,administration,and drug-related problems of this new ***:Various databases for drug review were used in this review like PubMed,Medline,Google scholar,Drug bank,***,Medscape,and European society of cardiology guidelines.A total of 58 articles were screened out of which 39 articles were included in this ***:This review discusses vericiguat s mechanism of action(cGMP pathway),clinical studies,application in the treatment of heart failure,and potential future considerations in therapeutic *** will also educate healthcare professionals about the new drug s pharmacokinetics and pharmacodynamics,dose,administration,and drug-related ***:After hospitalization for HFrEF,the 5-year survival rate is just 25%,and disease morbidity and death are stil *** adjunctive therapy for individuals with heart failure and a low ejection fraction,vericiguat has a moderate level of *** s efficacy as an adjunct therapy to different drugs used to cure HF has to be further *** s safety and dosage in patients w
维普期刊数据库